Abstract
Bronchioloalveolar carcinoma (BAC) is an important subtype of pulmonary adenocarcinoma. It has received increasing attention in recent years, due to its increasing incidence and its rate of sensitivity to epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKIs). This article reviews the epidemiology, risk factors, pathology, clinical presentation, and treatment of this disease. Special focus is paid to the emerging role of oral EGFR-TKIs in Bronchioloalveolar cell carcinoma.
MeSH terms
-
Adenocarcinoma, Bronchiolo-Alveolar* / epidemiology
-
Adenocarcinoma, Bronchiolo-Alveolar* / pathology
-
Adenocarcinoma, Bronchiolo-Alveolar* / therapy
-
Antineoplastic Agents / therapeutic use
-
ErbB Receptors / antagonists & inhibitors
-
Humans
-
Incidence
-
Lung Neoplasms* / epidemiology
-
Lung Neoplasms* / pathology
-
Lung Neoplasms* / therapy
-
Prognosis
-
Protein Kinase Inhibitors / therapeutic use
-
Risk Factors
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
ErbB Receptors